The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE) to develop the following guidance.
Technology appraisals:
- Dasatinib for the first line treatment of chronic myeloid leukaemia
- Decitabine for the treatment of acute myeloid leukaemia
The RCN is seeking nurses with knowledge and experience to participate in this work when it commences. Please contact caroline.rapu@rcn.org.uk by 30 April 2010, if you are interested in participating in this work on behalf of the RCN.